2023-08-24 07:58:18 ET
More on Cassava Sciences
- Cassava Sciences: CMS Data Promising But Many Red Flags Remain; Hold
- Cassava Sciences: Quest For Alzheimer's Treatment A Risky Bet On Simufilam
- Cassava Sciences' Simufilam For Alzheimer's Disease: Not As Good As Advertised
- Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
- Cassava Sciences Alzheimer’s drug simufilam outperforms in small trial
- Cassava Sciences adds 14% most since September
- Cassava Sciences falls 17% after reporting mid-stage data for Alzheimer’s candidate
For further details see:
Cassava Sciences spikes after insider purchase